Reata Pharmaceuticals, Inc. Class A(NASDAQ : RETA)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | 0.16% | 74.72 | 0.6% | $885.94m | |
| BMY | Bristol-Myers Squibb Company | -1.55% | 44.62 | 1.4% | $877.06m | |
| PFE | Pfizer Inc. | -0.10% | 39.38 | 0.9% | $827.25m | |
| JNJ | Johnson & Johnson | -0.49% | 139.22 | 0.7% | $818.89m | |
| LLY | Eli Lilly and Company | 0.43% | 118.00 | 1.0% | $657.11m | |
| ABBV | AbbVie, Inc. | 0.01% | 78.67 | 2.2% | $418.72m | |
| NVS | Novartis AG Sponsored ADR | 2.49% | 77.79 | 0.2% | $297.67m | |
| AZN | AstraZeneca PLC Sponsored ADR | 0.08% | 38.72 | 1.3% | $254.31m | |
| GSK | GlaxoSmithKline plc Sponsored ADR | -0.75% | 39.92 | 0.2% | $103.67m | |
| NVO | Novo Nordisk A/S Sponsored ADR Class B | -0.59% | 48.38 | 0.1% | $66.63m | |
| SNY | Sanofi Sponsored ADR | -0.55% | 41.48 | 0.2% | $35.58m | |
| LCI | Lannett Company, Inc. | -0.07% | 7.20 | 36.7% | $7.50m | |
| AKTX | Akari Therapeutics Plc Sponsored ADR | 3.09% | 4.00 | 1.6% | $5.96m | |
| EPIX | ESSA Pharma Inc | 4.46% | 2.40 | 0.1% | $0.03m |
Company Profile
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.